vs
Side-by-side financial comparison of ACNB CORP (ACNB) and LIFECORE BIOMEDICAL, INC. \DE\ (LFCR). Click either name above to swap in a different company.
ACNB CORP is the larger business by last-quarter revenue ($47.2M vs $31.1M, roughly 1.5× LIFECORE BIOMEDICAL, INC. \DE\). ACNB CORP runs the higher net margin — 22.9% vs -32.1%, a 55.0% gap on every dollar of revenue. On growth, ACNB CORP posted the faster year-over-year revenue change (42.2% vs -4.5%). ACNB CORP produced more free cash flow last quarter ($52.6M vs $25.0K). Over the past eight quarters, ACNB CORP's revenue compounded faster (22.1% CAGR vs -0.1%).
ACNB Corp is a US-based financial holding company headquartered in Pennsylvania. It provides a full suite of financial solutions including retail and commercial banking, wealth management, trust services, and property & casualty insurance products. Its core market covers local communities, individual consumers, and small-to-medium enterprises across south-central Pennsylvania and northern Maryland.
LIFECORE BIOMEDICAL, INC. is a biomedical firm focused on developing and manufacturing high-quality hyaluronic acid-based biomaterials. It operates three core segments: medical application products, pharmaceutical solutions, and personal care ingredients, with main markets spanning North America, Europe and the Asia-Pacific, supplying to leading medical device, pharmaceutical and cosmetic brand partners.
ACNB vs LFCR — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $47.2M | $31.1M |
| Net Profit | $10.8M | $-10.0M |
| Gross Margin | — | 25.0% |
| Operating Margin | 27.9% | -9.9% |
| Net Margin | 22.9% | -32.1% |
| Revenue YoY | 42.2% | -4.5% |
| Net Profit YoY | 63.8% | -52.0% |
| EPS (diluted) | $1.10 | $-0.29 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $47.2M | — | ||
| Q3 25 | $50.9M | $31.1M | ||
| Q2 25 | $50.3M | — | ||
| Q1 25 | $43.5M | $35.2M | ||
| Q4 24 | $33.2M | $32.6M | ||
| Q3 24 | $34.1M | $24.7M | ||
| Q2 24 | $33.3M | — | ||
| Q1 24 | $31.6M | $35.7M |
| Q4 25 | $10.8M | — | ||
| Q3 25 | $14.9M | $-10.0M | ||
| Q2 25 | $11.6M | — | ||
| Q1 25 | $-272.0K | $-14.8M | ||
| Q4 24 | $6.6M | $-6.6M | ||
| Q3 24 | $7.2M | $-16.2M | ||
| Q2 24 | $11.3M | — | ||
| Q1 24 | $6.8M | $15.6M |
| Q4 25 | — | — | ||
| Q3 25 | — | 25.0% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 28.0% | ||
| Q4 24 | — | 34.0% | ||
| Q3 24 | — | 21.8% | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 33.3% |
| Q4 25 | 27.9% | — | ||
| Q3 25 | 37.2% | -9.9% | ||
| Q2 25 | 29.7% | — | ||
| Q1 25 | -1.3% | -25.7% | ||
| Q4 24 | 24.8% | -6.0% | ||
| Q3 24 | 27.6% | -46.9% | ||
| Q2 24 | 42.8% | — | ||
| Q1 24 | 26.9% | -2.5% |
| Q4 25 | 22.9% | — | ||
| Q3 25 | 29.2% | -32.1% | ||
| Q2 25 | 23.2% | — | ||
| Q1 25 | -0.6% | -42.0% | ||
| Q4 24 | 19.9% | -20.2% | ||
| Q3 24 | 21.1% | -65.7% | ||
| Q2 24 | 33.9% | — | ||
| Q1 24 | 21.4% | 43.8% |
| Q4 25 | $1.10 | — | ||
| Q3 25 | $1.42 | $-0.29 | ||
| Q2 25 | $1.11 | — | ||
| Q1 25 | $-0.03 | $-0.47 | ||
| Q4 24 | $0.77 | $-0.25 | ||
| Q3 24 | $0.84 | $-0.53 | ||
| Q2 24 | $1.32 | — | ||
| Q1 24 | $0.80 | $0.42 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $65.6M | $18.9M |
| Total DebtLower is stronger | $255.4M | $136.0M |
| Stockholders' EquityBook value | $420.0M | $-10.5M |
| Total Assets | $3.2B | $235.2M |
| Debt / EquityLower = less leverage | 0.61× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $65.6M | — | ||
| Q3 25 | $102.1M | $18.9M | ||
| Q2 25 | $103.1M | — | ||
| Q1 25 | $123.6M | $5.4M | ||
| Q4 24 | $47.3M | $9.5M | ||
| Q3 24 | $58.1M | — | ||
| Q2 24 | $86.3M | — | ||
| Q1 24 | $53.1M | — |
| Q4 25 | $255.4M | — | ||
| Q3 25 | $255.4M | $136.0M | ||
| Q2 25 | $255.4M | — | ||
| Q1 25 | $255.3M | $124.9M | ||
| Q4 24 | $255.3M | $111.3M | ||
| Q3 24 | $255.3M | $106.3M | ||
| Q2 24 | $255.3M | — | ||
| Q1 24 | $255.3M | $97.1M |
| Q4 25 | $420.0M | — | ||
| Q3 25 | $408.6M | $-10.5M | ||
| Q2 25 | $395.2M | — | ||
| Q1 25 | $386.9M | $2.2M | ||
| Q4 24 | $303.3M | $15.4M | ||
| Q3 24 | $306.8M | $-3.9M | ||
| Q2 24 | $289.3M | — | ||
| Q1 24 | $279.9M | $17.7M |
| Q4 25 | $3.2B | — | ||
| Q3 25 | $3.3B | $235.2M | ||
| Q2 25 | $3.3B | — | ||
| Q1 25 | $3.3B | $237.7M | ||
| Q4 24 | $2.4B | $255.4M | ||
| Q3 24 | $2.4B | $246.8M | ||
| Q2 24 | $2.5B | — | ||
| Q1 24 | $2.4B | $246.2M |
| Q4 25 | 0.61× | — | ||
| Q3 25 | 0.62× | — | ||
| Q2 25 | 0.65× | — | ||
| Q1 25 | 0.66× | 56.05× | ||
| Q4 24 | 0.84× | 7.20× | ||
| Q3 24 | 0.83× | — | ||
| Q2 24 | 0.88× | — | ||
| Q1 24 | 0.91× | 5.49× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $53.6M | $1.8M |
| Free Cash FlowOCF − Capex | $52.6M | $25.0K |
| FCF MarginFCF / Revenue | 111.4% | 0.1% |
| Capex IntensityCapex / Revenue | 2.3% | 5.6% |
| Cash ConversionOCF / Net Profit | 4.96× | — |
| TTM Free Cash FlowTrailing 4 quarters | $92.2M | $-16.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $53.6M | — | ||
| Q3 25 | $23.2M | $1.8M | ||
| Q2 25 | $17.8M | — | ||
| Q1 25 | $-71.0K | $1.2M | ||
| Q4 24 | $39.8M | $-6.1M | ||
| Q3 24 | $13.6M | $-613.0K | ||
| Q2 24 | $9.7M | — | ||
| Q1 24 | $10.8M | $-1.4M |
| Q4 25 | $52.6M | — | ||
| Q3 25 | $22.8M | $25.0K | ||
| Q2 25 | $17.6M | — | ||
| Q1 25 | $-730.0K | $-4.3M | ||
| Q4 24 | $38.8M | $-8.6M | ||
| Q3 24 | $13.3M | $-4.0M | ||
| Q2 24 | $9.4M | — | ||
| Q1 24 | $10.7M | $-7.8M |
| Q4 25 | 111.4% | — | ||
| Q3 25 | 44.7% | 0.1% | ||
| Q2 25 | 35.0% | — | ||
| Q1 25 | -1.7% | -12.1% | ||
| Q4 24 | 117.0% | -26.3% | ||
| Q3 24 | 39.1% | -16.3% | ||
| Q2 24 | 28.3% | — | ||
| Q1 24 | 33.9% | -21.8% |
| Q4 25 | 2.3% | — | ||
| Q3 25 | 0.8% | 5.6% | ||
| Q2 25 | 0.4% | — | ||
| Q1 25 | 1.5% | 15.5% | ||
| Q4 24 | 2.9% | 7.5% | ||
| Q3 24 | 0.7% | 13.9% | ||
| Q2 24 | 0.9% | — | ||
| Q1 24 | 0.2% | 17.8% |
| Q4 25 | 4.96× | — | ||
| Q3 25 | 1.56× | — | ||
| Q2 25 | 1.52× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 6.03× | — | ||
| Q3 24 | 1.88× | — | ||
| Q2 24 | 0.86× | — | ||
| Q1 24 | 1.60× | -0.09× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ACNB
Segment breakdown not available.
LFCR
| Transferred At Point In Time | $26.6M | 85% |
| Transferred Over Time | $4.5M | 15% |
